Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. HAE
stocks logo

HAE

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q3
FY2026Q4
FY2027Q1
331.90M
-4.78%
1.250
+5.07%
337.42M
+2.06%
1.297
+4.59%
337.69M
+5.07%
1.235
+12.31%
Estimates Revision
The market is revising Upward the revenue expectations for Haemonetics Corporation (HAE) for FY2026, with the revenue forecasts being adjusted by 1.48% over the past three months. During the same period, the stock price has changed by 54.12%.
Revenue Estimates for FY2026
Revise Upward
up Image
+1.48%
In Past 3 Month
EPS Estimates for FY2026
Revise Upward
up Image
+1.83%
In Past 3 Month
Stock Price
Go Up
up Image
+54.12%
In Past 3 Month
Wall Street analysts forecast HAE stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for HAE is 78.86 USD with a low forecast of 64.00 USD and a high forecast of 90.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
Wall Street analysts forecast HAE stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for HAE is 78.86 USD with a low forecast of 64.00 USD and a high forecast of 90.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 83.810
sliders
Low
64.00
Averages
78.86
High
90.00
Current: 83.810
sliders
Low
64.00
Averages
78.86
High
90.00
Mizuho
Outperform
maintain
$65 -> $75
2025-11-10
Reason
Mizuho
Price Target
$65 -> $75
2025-11-10
maintain
Outperform
Reason
Mizuho raised the firm's price target on Haemonetics to $75 from $65 and keeps an Outperform rating on the shares following the fiscal Q2 report. The post-earnings rally reflects stock the better than expected earnings on top of some short covering, the analyst tells investors in a research note. The firm sees an improved margin trajectory for Haemonetics.
Baird
David Rescott
Outperform
maintain
$65 -> $82
2025-11-07
Reason
Baird
David Rescott
Price Target
$65 -> $82
2025-11-07
maintain
Outperform
Reason
Baird analyst David Rescott raised the firm's price target on Haemonetics to $82 from $65 and keeps an Outperform rating on the shares.
Barrington
Outperform
maintain
$86 -> $90
2025-11-07
Reason
Barrington
Price Target
$86 -> $90
2025-11-07
maintain
Outperform
Reason
Barrington raised the firm's price target on Haemonetics to $90 from $86 and keeps an Outperform rating on the shares after a Q2 beat and FY26 guidance raise.
BofA
Underperform -> Neutral
upgrade
$58 -> $75
2025-11-07
Reason
BofA
Price Target
$58 -> $75
2025-11-07
upgrade
Underperform -> Neutral
Reason
BofA upgraded Haemonetics to Neutral from Underperform with a price target of $75, up from $58. Plasma volume growth returned to high single digits in the U.S. this quarter and double digits in Europe, notes the analyst, who thinks Haemonetics is taking a "more prudent view" on its guidance philosophy.
BTIG
Buy
maintain
$85 -> $88
2025-11-06
Reason
BTIG
Price Target
$85 -> $88
2025-11-06
maintain
Buy
Reason
BTIG raised the firm's price target on Haemonetics to $88 from $85 and keeps a Buy rating on the shares after the company beat expectations across all business segments, reset Hospital guidance to "an achievable level," and raised the total sales outlook for FY26. Arguing that this quarter's execution was a positive lift for credibility on both operations and messaging, the firm thinks shares can continue "a gradual recovery from here," the analyst tells investors.
Raymond James
Strong Buy
to
Outperform
downgrade
$105 -> $78
2025-08-11
Reason
Raymond James
Price Target
$105 -> $78
2025-08-11
downgrade
Strong Buy
to
Outperform
Reason
Raymond James downgraded Haemonetics to Outperform from Strong Buy with a price target of $78, down from $105. The firm also removed the shares from its Analyst Current Favorite list. Haemonetics' interventional technologies franchise declined in Q2 due to issues around selling execution, the analyst tells investors in a research note. Raymond James views the issues as fixable, but its confidence on the execution and timing of doing so has waned. The firm continues to view Haemonetics as an attractive and undervalued asset.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Haemonetics Corp (HAE.N) is 16.20, compared to its 5-year average forward P/E of 21.39. For a more detailed relative valuation and DCF analysis to assess Haemonetics Corp 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
21.39
Current PE
16.20
Overvalued PE
28.47
Undervalued PE
14.32

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
13.71
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
17.82
Undervalued EV/EBITDA
9.59

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
3.23
Current PS
0.00
Overvalued PS
4.21
Undervalued PS
2.25
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

HAE News & Events

Events Timeline

(ET)
2025-11-06
12:01:15
Haemonetics Sees 26.1% Increase
select
2025-11-06
06:20:30
Haemonetics Revises FY26 Adjusted EPS Forecast to $4.80-$5.00, Down from $4.70-$5.00
select
2025-11-06
06:17:41
Haemonetics announces Q2 adjusted EPS of $1.27, surpassing consensus estimate of $1.11
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
8.5
12-02Benzinga
Two Health Care Stocks You Might Consider Selling This Month

  • Exact Sciences Corp Acquisition: Abbott Laboratories is set to acquire Exact Sciences for $105 per share, totaling approximately $21 billion, marking the largest deal in the global health-care sector this year. Exact Sciences' stock has surged 51% recently, with an RSI of 89.8.

  • Haemonetics Corp Earnings Report: Haemonetics reported strong second-quarter earnings of $1.27 per share, exceeding expectations, and raised its FY2026 EPS guidance. The stock has increased by 61% over the past month, with an RSI of 89.4.

  • Momentum Indicators: Both Exact Sciences and Haemonetics are considered overbought based on their high RSI values, which indicate strong momentum but may signal potential risks for investors.

  • Market Performance: Despite recent gains, shares of Exact Sciences and Haemonetics experienced slight declines on the latest trading day, closing at $101.20 and $80.96, respectively.

[object Object]
Preview
4.0
11-26NASDAQ.COM
Haemonetics Achieves Analyst Price Target

  • Current Stock Performance: Haemonetics Corp. shares have surpassed the average analyst 12-month target price of $80.40, trading at $80.63/share, prompting potential analyst reactions regarding valuation adjustments.

  • Analyst Target Range: There are varying analyst targets for Haemonetics, with estimates ranging from $62.00 to $100.00, indicating a standard deviation of $12.02 among the 10 analysts contributing to the average.

  • Investor Considerations: The stock's rise above the average target price signals investors to evaluate whether the price is likely to increase further or if it has become overvalued, suggesting a potential need to reassess their positions.

  • Analyst Ratings Overview: The article references a rating scale from 1 (Strong Buy) to 5 (Strong Sell) for Haemonetics, reflecting the collective insights of analysts covering the company.

[object Object]
Preview
5.0
11-08NASDAQ.COM
SG Capital Sells Almost 732,000 Shares of Haemonetics Valued at $59.1 Million

  • SG Capital's Share Sale: SG Capital Management LLC sold 731,892 shares of Haemonetics Corporation, reducing its stake to 175,000 shares, which now represents 0.8% of its assets under management.

  • Haemonetics' Financial Performance: The company reported a 5% decline in revenue for the fiscal second quarter, with management projecting a slight improvement in full-year revenue guidance.

  • Market Reaction: Following the earnings release, Haemonetics' share price increased by 35%, despite ongoing concerns about its revenue growth.

  • 3G Capital's Exit Strategy: 3G Capital is likely exiting its position in Haemonetics after significantly reducing its stake, as the company's shares have underperformed compared to the S&P 500 index.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Haemonetics Corp (HAE) stock price today?

The current price of HAE is 83.81 USD — it has increased 2.32 % in the last trading day.

arrow icon

What is Haemonetics Corp (HAE)'s business?

Haemonetics Corporation is a global healthcare company. The Company is engaged in providing a suite of medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. The Company’s technology addresses various medical markets, including blood and plasma component collection, the surgical suite, and hospital transfusion services. The Company’s Plasma segment includes plasma collection devices and disposables, donor management software and supporting software solutions sold to plasma customers. Its Blood Center segment manufactures and provides customers with its full line of apheresis solutions for automated blood collection. The Company’s Hospital segment consists of Interventional Technologies, which includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection products, and Blood Management Technologies, which includes Hemostasis Management, Cell Salvage and Transfusion Management products.

arrow icon

What is the price predicton of HAE Stock?

Wall Street analysts forecast HAE stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for HAE is 78.86 USD with a low forecast of 64.00 USD and a high forecast of 90.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Haemonetics Corp (HAE)'s revenue for the last quarter?

Haemonetics Corp revenue for the last quarter amounts to 327.32M USD, decreased -5.27 % YoY.

arrow icon

What is Haemonetics Corp (HAE)'s earnings per share (EPS) for the last quarter?

Haemonetics Corp. EPS for the last quarter amounts to 0.81 USD, increased 22.73 % YoY.

arrow icon

What changes have occurred in the market's expectations for Haemonetics Corp (HAE)'s fundamentals?

The market is revising Upward the revenue expectations for Haemonetics Corporation (HAE) for FY2026, with the revenue forecasts being adjusted by 1.48% over the past three months. During the same period, the stock price has changed by 54.12%.
arrow icon

How many employees does Haemonetics Corp (HAE). have?

Haemonetics Corp (HAE) has 3023 emplpoyees as of December 05 2025.

arrow icon

What is Haemonetics Corp (HAE) market cap?

Today HAE has the market capitalization of 3.92B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free